MSLE
$7.31
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the ...
Recent News
Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference
Satellos Bioscience (MSCL.TO, NASDAQ: MSLE) was at last look up near 10% in US premarket trade Tuesd
Satellos price target raised to $40 from $5 at Oppenheimer
Oppenheimer raised the firm’s price target on Satellos (MSLE) to $40 from $5 and keeps an Outperform rating on the shares. The firm is updating its model for U.S. listing, and adjusting for 1:12 reverse split and its increase in Duchenne muscular dystrophy market penetration. Oppenheimer sees Satellos as an arbitrage opportunity in DMD space, wherein SAT-3247 Phase II randomized data could move Satellos up 300%-500%/-90%. President's Day Sale - 70% OffUnlock hedge fund-level data and powerful in
Satellos Closes US$57.2 Million Public Offering in Canada and the United States
Satellos Bioscience (MSCL.TO, MSLE) was last seen down 2% in after-hours Nasdaq trading after the co